Liver injury during rivaroxaban treatment in a patient with AL amyloidosis
- 11 January 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 77 (7), 1073-1076
- https://doi.org/10.1007/s00228-020-03084-8
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Liver injury caused by oral anticoagulants: A population-based retrospective cohort studyLiver International, 2020
- Contrasting Role of Concentration in Rivaroxaban Induced Toxicity and Oxidative Stress in Isolated Kidney MitochondriaDrug Research, 2019
- Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019Frontiers in Pharmacology, 2019
- EASL Clinical Practice Guidelines: Drug-induced liver injuryJournal of Hepatology, 2019
- Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic EffectCancers, 2019
- Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patientsVascular Health and Risk Management, 2019
- The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated ThrombosisCancers, 2018
- Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismThe New England Journal of Medicine, 2018
- Mechanisms of Drug-induced Liver InjuryClinics in Liver Disease, 2013
- Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac AmyloidosisCirculation, 2009